Chang Gung medical journal · 2010
Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Chih-Hung, Lee Chuan-Mo, Chen Chien-Hung, Hu Tsung-Hui, Wang Jing-Houng, Hung Chao-Hung, Chung Ching-Hu, Lu Sheng-Nan
Аннотация
BACKGROUND: Chronic hepatitis C (CHC) is frequently associated with the presence of serum autoantibodies. The prevalence and clinical relevance of serum autoantibodies in CHC patients and their influence on antiviral treatment have not been well established.
METHODS: From February 1999 to July 2004, 460 consecutive adult patients with CHC were studied. Antinuclear antibody (ANA) and smooth muscle antibody (SMA) were determined by indirect immunofluorescence. The presence of these antibodies was related to patient characteristics and to the outcome of 24 weeks of therapy with interferon (IFN) alfa-2b (n=376) or pegylated- IFN alfa-2b (n=84) plus ribavirin.
RESULTS: The prevalence of ANA and SMA was 7.4% and 19.3%, respectively. Seropositivity for ANA and/or SMA was associated with old age and high aspartate aminotransferase (AST) levels. The rates of sustained virological response and early withdrawal of therapy were comparable between autoantibody- positive and -negative patients. None of the autoantibody-positive patients experienced a flare-up of transaminase during treatment, or developed severe systemic autoimmune disease.
CONCLUSION: Serum ANA and/or SMA-positive HCV-infected patients are older, and have higher disease activity and severity than their negative counterparts. However, the presence of ANA or SMA did not influence the response to combination antiviral therapy, which is safe and effective in autoantibody--positive CHC patients.
METHODS: From February 1999 to July 2004, 460 consecutive adult patients with CHC were studied. Antinuclear antibody (ANA) and smooth muscle antibody (SMA) were determined by indirect immunofluorescence. The presence of these antibodies was related to patient characteristics and to the outcome of 24 weeks of therapy with interferon (IFN) alfa-2b (n=376) or pegylated- IFN alfa-2b (n=84) plus ribavirin.
RESULTS: The prevalence of ANA and SMA was 7.4% and 19.3%, respectively. Seropositivity for ANA and/or SMA was associated with old age and high aspartate aminotransferase (AST) levels. The rates of sustained virological response and early withdrawal of therapy were comparable between autoantibody- positive and -negative patients. None of the autoantibody-positive patients experienced a flare-up of transaminase during treatment, or developed severe systemic autoimmune disease.
CONCLUSION: Serum ANA and/or SMA-positive HCV-infected patients are older, and have higher disease activity and severity than their negative counterparts. However, the presence of ANA or SMA did not influence the response to combination antiviral therapy, which is safe and effective in autoantibody--positive CHC patients.